Efficacy and Safety of Dupilumab for the Treatment of adult Atopic Dermatitis:A meta-analysis of randomized clinical trials
详细信息 查看官网全文
- 英文论文题名：Efficacy and Safety of Dupilumab for the Treatment of adult Atopic Dermatitis:A meta-analysis of randomized clinical trials
- 论文作者：Han Yue
- 英文论文作者：Han Yue ; Institute of Dermatology ; Chinese Academy of Medical Sciences and Peking Union Medical College
- 年：2016
- 作者机构：Institute of Dermatology,Chinese Academy of Medical Sciences and Peking Union Medical College;
- 英文论文关键词：Dupilumab ; meta-analysis ; atopic dermatitis ; efficacy ; safety
- 会议召开时间：2016-11-04
- 会议录名称：第十一届全国免疫学学术大会壁报交流集
- 英文会议录名称：Proceedings of 2016 CSI Congress on Immunology
- 语种：英文
- 分类号：R758.2
- 学会代码：IGMD
- 会议名称：第十一届全国免疫学学术大会
- 会议地点：中国安徽合肥
- 主办单位：中国免疫学会
- 学会名称：中国免疫学会
- 页数：2
- 文件大小：1344k
- 原文格式：D
- 会议级别：全国
摘要
Background:Dupilumab is a recently developed fully human monoclonal antibody targeting the interleukin-4 receptor(IL-4R) α subunit,which blocks both interleukin-4(IL-4) and IL-13.Several clinical trials have demonstrated that Dupilumab treatment significantly alleviated the symptoms of atopic dermatitis(AD) without serious adverse effects.Objective:We sought to analyze the efficacy and safety of Dupilumab for the treatment of AD in a meta-analysis of clinical trial results.Methods:We searched the Pub Med,Medline,Embase,and Web of Science databases for suitable trials,and included only double-blind,randomized,placebo-controlled studies with Dupilumab-treated versus placebo-treated patients with AD.A systematic meta-analysis of randomized trials was performed to analyze the effect of Dupilumab on clinical indexes that correlated with the severity of AD and the safety profile of Dupilumab.Results:A total of five clinical trials were selected in our meta-analysis(N=587 adult participants,with moderate to se-vere AD).Among adult patients with moderate-to-severe atopic dermatitis,Dupilumab treatment yielded a significant improvement in clinical signs and symptoms of atopic dermatitis compared to placebo treatment.Furthermore,Dupilumab treatment did not show serious adverse effects as other systematic therapeutic drugs did,indicating that Dupilumab treatment is safe and well tolerated.Conclusion:Dupilumab is a promising therapeutic strategy that improves the management of adult patients with moderate to severe AD.
Background:Dupilumab is a recently developed fully human monoclonal antibody targeting the interleukin-4 receptor(IL-4R) α subunit,which blocks both interleukin-4(IL-4) and IL-13.Several clinical trials have demonstrated that Dupilumab treatment significantly alleviated the symptoms of atopic dermatitis(AD) without serious adverse effects.Objective:We sought to analyze the efficacy and safety of Dupilumab for the treatment of AD in a meta-analysis of clinical trial results.Methods:We searched the Pub Med,Medline,Embase,and Web of Science databases for suitable trials,and included only double-blind,randomized,placebo-controlled studies with Dupilumab-treated versus placebo-treated patients with AD.A systematic meta-analysis of randomized trials was performed to analyze the effect of Dupilumab on clinical indexes that correlated with the severity of AD and the safety profile of Dupilumab.Results:A total of five clinical trials were selected in our meta-analysis(N=587 adult participants,with moderate to se-vere AD).Among adult patients with moderate-to-severe atopic dermatitis,Dupilumab treatment yielded a significant improvement in clinical signs and symptoms of atopic dermatitis compared to placebo treatment.Furthermore,Dupilumab treatment did not show serious adverse effects as other systematic therapeutic drugs did,indicating that Dupilumab treatment is safe and well tolerated.Conclusion:Dupilumab is a promising therapeutic strategy that improves the management of adult patients with moderate to severe AD.
Background:Dupilumab is a recently developed fully human monoclonal antibody targeting the interleukin-4 receptor(IL-4R) α subunit,which blocks both interleukin-4(IL-4) and IL-13.Several clinical trials have demonstrated that Dupilumab treatment significantly alleviated the symptoms of atopic dermatitis(AD) without serious adverse effects.Objective:We sought to analyze the efficacy and safety of Dupilumab for the treatment of AD in a meta-analysis of clinical trial results.Methods:We searched the Pub Med,Medline,Embase,and Web of Science databases for suitable trials,and included only double-blind,randomized,placebo-controlled studies with Dupilumab-treated versus placebo-treated patients with AD.A systematic meta-analysis of randomized trials was performed to analyze the effect of Dupilumab on clinical indexes that correlated with the severity of AD and the safety profile of Dupilumab.Results:A total of five clinical trials were selected in our meta-analysis(N=587 adult participants,with moderate to se-vere AD).Among adult patients with moderate-to-severe atopic dermatitis,Dupilumab treatment yielded a significant improvement in clinical signs and symptoms of atopic dermatitis compared to placebo treatment.Furthermore,Dupilumab treatment did not show serious adverse effects as other systematic therapeutic drugs did,indicating that Dupilumab treatment is safe and well tolerated.Conclusion:Dupilumab is a promising therapeutic strategy that improves the management of adult patients with moderate to severe AD.
引文